You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR PROGLYCEM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROGLYCEM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00892073 ↗ Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed The Hospital for Sick Children Phase 2 2006-05-01 To study the effect of combined diazoxide-metformin therapy on body weight in youth with hypothalamic obesity following treatment for craniopharyngioma. A secondary objective is to evaluate changes in insulin resistance (IR), beta-cell function, features of the metabolic syndrome, muscle metabolism and intramyocellular lipid. Hypothesis: Treatment with diazoxide and metformin will result in weight loss or slowed weight gain and improved metabolic profile, compared to pretreatment levels.
NCT00987168 ↗ Sandostatine® LP and Hyperinsulinism Completed Novartis Phase 2 2009-05-01 To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.
NCT00987168 ↗ Sandostatine® LP and Hyperinsulinism Completed Assistance Publique - Hôpitaux de Paris Phase 2 2009-05-01 To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.
NCT03540758 ↗ Regulation of Endogenous Glucose Production by Central KATP Channels Recruiting National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2018-08-01 Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
NCT03540758 ↗ Regulation of Endogenous Glucose Production by Central KATP Channels Recruiting National Institutes of Health (NIH) Phase 2 2018-08-01 Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
NCT03540758 ↗ Regulation of Endogenous Glucose Production by Central KATP Channels Recruiting Albert Einstein College of Medicine Phase 2 2018-08-01 Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
NCT03540758 ↗ Regulation of Endogenous Glucose Production by Central KATP Channels Recruiting Albert Einstein College of Medicine, Inc. Phase 2 2018-08-01 Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROGLYCEM

Condition Name

Condition Name for PROGLYCEM
Intervention Trials
Glucose, High Blood 3
Diabetes Mellitus, Type 2 2
Glucose Metabolism Disorders 2
Glucose Metabolism Disorders (Including Diabetes Mellitus) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROGLYCEM
Intervention Trials
Metabolic Diseases 3
Hyperglycemia 3
Glucose Metabolism Disorders 3
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROGLYCEM

Trials by Country

Trials by Country for PROGLYCEM
Location Trials
United States 4
France 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PROGLYCEM
Location Trials
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROGLYCEM

Clinical Trial Phase

Clinical Trial Phase for PROGLYCEM
Clinical Trial Phase Trials
Phase 2 5
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROGLYCEM
Clinical Trial Phase Trials
Recruiting 2
Suspended 2
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROGLYCEM

Sponsor Name

Sponsor Name for PROGLYCEM
Sponsor Trials
Albert Einstein College of Medicine 3
Albert Einstein College of Medicine, Inc. 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROGLYCEM
Sponsor Trials
Other 9
NIH 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.